Structural Insights into the Recruitment of SMRT by the Corepressor SHARP under Phosphorylative Regulation  by Mikami, Suzuka et al.
Structure
ArticleStructural Insights into the Recruitment
of SMRT by the Corepressor SHARP
under Phosphorylative Regulation
Suzuka Mikami,1,4 Teppei Kanaba,1,4 Naoki Takizawa,2,4 Ayaho Kobayashi,1,4 Ryoko Maesaki,1,3 Toshinobu Fujiwara,2,5
Yutaka Ito,1 and Masaki Mishima1,*
1Graduate School of Science and Engineering, Tokyo Metropolitan University, 1-1 Minamiosawa Hachioji 192-0397, Japan
2Institute of Microbial Chemistry, Tokyo 3-14-23 Kamiosaki, Shinagawa-ku 141-0021, Japan
3Graduate School of Bioscience, Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara 630-0192, Japan
4These authors contributed equally to this work
5Present address: Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuho-ku, Nagoya 467-8603,
Japan
*Correspondence: mishima-masaki@tmu.ac.jp
http://dx.doi.org/10.1016/j.str.2013.10.007SUMMARY
The transcriptional corepressors SMRT/NCoR, com-
ponents of histone deacetylase complexes, interact
with nuclear receptors and many other transcription
factors. SMRT is a target for the ubiquitously ex-
pressed protein kinase CK2, which is known to phos-
phorylate a wide variety of substrates. Increasing
evidence suggests that CK2 plays a regulatory role
in many cellular events, particularly, in transcription.
However, little is known about the precise mode of
action involved. Here, we report the three-dimen-
sional structure of a SMRT/HDAC1-associated
repressor protein (SHARP) in complex with phos-
phorylated SMRT, as determined by solution NMR.
Phosphorylation of the CK2 site on SMRT signifi-
cantly increased affinity for SHARP. We also
confirmed the significance of CK2 phosphorylation
by reporter assay and propose a mechanism
involving the process of phosphorylation acting
as a molecular switch. Finally, we propose that
the SPOC domain functions as a phosphorylation
binding module.
INTRODUCTION
SMRT/HDAC1-associated repressor protein (SHARP) is a tran-
scriptional corepressor that was identified independently in nu-
clear receptor and Notch/RBP-Jk signaling pathways (Oswald
et al., 2002; Shi et al., 2001). SHARP is characterized by N-termi-
nal RNA recognitionmotifs (RRMs) and a highly conservedC-ter-
minal Spen paralog and ortholog C-terminal (SPOC) domain. The
RRMdomains of SHARP bind the steroid hormone receptor acti-
vator (SRA) (Newberry et al., 1999; Shi et al., 2001), which is
emerging as a functional RNA acting as both noncoding RNA
and coding RNA (Colley and Leedman, 2011; Cooper et al.,
2011; Lanz et al., 2002; Novikova et al., 2012). SRA itself is a
coactivator for transcription regulated by the nuclear hormoneStructure 22receptor, and SRA protein (SRAP) coded by SRA acts as a core-
pressor of SRA. The SPOC domain of SHARP directly interacts
with the transcriptional corepressors silencing mediator for reti-
noid and thyroid receptor (SMRT)/nuclear receptor corepressor
(NCoR), which are well-known components of HDAC com-
plexes. Via SMRT/NcoR, SHARP recruits HDAC and thus
represses transcription. Transactivation by the glucocorticoid
receptor and estrogen receptor is thought to exert negative
feedback via the expression of SHARP (Shi et al., 2001).
SMRT and NCoR are large corepressors and are considered
to be unstructured for the most part, share high similarity, and
interact with multiple transcriptional factors and coregulators.
They act as ‘‘platform proteins’’ in recruiting a corepressor com-
plex (Watson et al., 2012a). The N-terminal regions of SMRT/
NCoR bind to both transducin beta-like protein 1 (TBL1) and G
protein pathway suppressor 2 (GPS2), forming a three-way com-
plex that represents the core of a multimeric structure (Oberoi
et al., 2011). The LSD motif, located at the acidic C-terminal
tail of SMRT/NCoR, was suggested as being responsible for
binding to the SPOC domain of SHARP (Ariyoshi and Schwabe,
2003; Shi et al., 2001). In addition, it was shown that the second
residue (Ser) of the LSD motif is a phosphorylation site for CK2,
which is reported to be phosphorylated in cells (Olsen et al.,
2006; Zhou et al., 2001). Nevertheless, little is known about the
role of this phosphorylative event.
As a signaling protein, CK2 is a promiscuous kinase that has
many cellular functions associated with a wide repertoire of sub-
strates located in a variety of cellular compartments (Duncan
et al., 2010; Litchfield, 2003; Pinna, 2002). Notably, a number
of transcriptional factors are known to be phosphorylated by
CK2. In fact, Meggio and Pinna (2003) reported that 60 of 307
putative substrates were transcriptional factors. Thus, the role
of phosphorylation upon transcriptional factors by CK2 is an
important issue. Nevertheless, the molecular basis, and mode
of action, of transcriptional regulation by CK2 remains largely
unknown because of the lack of structure-based evidence, and
because of complexities associated with the promiscuity of
CK2, althoughmany observations concerning CK2 phosphoryla-
tion have been documented (Meggio and Pinna, 2003). This is in
stark contrast to the more well-studied transcriptional factors,
such as AP1, STAT, and SMADs, which are phosphorylated, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 35
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Figure 1. Schematic Representations of SHARP and SMRT
(A) Schematic representations of the domain structure of human SHARP and human SMRT. RRM (RNA recognition motif), RID (nuclear receptor interaction
domain), RBPID (RBP interaction domain), and SPOCdomains are indicated in SHARP, andGPS2- and TBL1-interacting regions, SANT-like domains, and ID and
LSD motifs are indicated in SMRT.
(B) Sequence alignments of C-terminal regions of SMRT, NCoR, and SMRTER. The putative CK1 site (S/T-X-X-X-S) and CK2 site (S/T-X-X-E) are also indicated.
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SPOC Domain Recognizes CK2 Phosphorylation of SMRTand regulated by their own specific kinases in signal transduc-
tion pathways (Darnell et al., 1994; Johnson and Lapadat,
2002; Kretzschmar and Massague´, 1998).
The crystal structure of the SPOC domain from SHARP has
already been reported (Ariyoshi and Schwabe, 2003). However,
the structure of the SPOC/SMRT complex has not yet been re-
ported, and characterization of its molecular interaction has
been elusive. Here, we demonstrate that the phosphorylation
of SMRT by CK2 markedly enhances interaction with the
SPOC domain of SHARP as a phosphorylation-recognizing
domain. We present the structure determination of the SPOC
domain of SHARP/phosphorylated SMRT peptide complex, as
determined by nuclear magnetic resonance (NMR). We also pre-
sent the molecular recognition mechanism of phosphorylated
SMRT by SHARP, as revealed by structural analysis in conjunc-
tion with surface plasmon resonance (SPR) and reporter assays.
We thus present a compelling structure-based example in which
phosphorylation by CK2 regulates transcription.
RESULTS
The SPOC Domain of SHARP Preferentially Binds
Phosphorylated SMRT
Although theC-terminal LSDmotif of SMRTwas suggested to be
important for direct interaction with the SPOC domain (Fig-
ure 1A), the role of phosphorylation upon S2522 in the LSD motif
has not been identified. Furthermore, a database search based
on aCK1 phosphorylation consensus sequence (S/TXXXS) using
the Scansite server (http://scansite.mit.edu/) showed that the
S2524 adjacent to the LSD motif was a putative CK1 site
(TLSDSE) (Figure 1B). Thus, we initially investigated the effects36 Structure 22, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rightsof phosphorylation using the recombinant SPOC domain (aa
3496–3664) and a 24-residue C-terminal SMRT peptide (aa
2502–2525). When the peptide was not phosphorylated, NMR
titration experiment exhibited low affinity because the chemical
shift changes of the SPOC domain signals upon unlabeled
SMRT peptide binding demonstrated fast exchange, a feature
that is typically observed in cases of weak binding (Figure 2A,
left panel). In contrast, NMR titration experiments using the dou-
ble phosphorylated peptide, in which both S2522 and S2524
(CK2 and putative CK1 site, respectively) were phosphorylated,
showed binding in a slow exchange manner, which is typically
observed in cases of stable binding (Figure 2A, right panel).
We next estimated the minimal length of phosphorylated
SMRT required for interaction with the SPOC domain by com-
parison of NMR titration experiments using phosphorylated 24-
(aa 2502–2525), 8- (aa 2518–2525), and 5- (aa 2521–2525)
residue peptides (Figure 2B; Figure S1 available online). As a
result, the 8-residue peptide showed an almost identical chem-
ical shift perturbation pattern to that of the 24-residue peptide
in slow exchange manner, although the magnitude of the chem-
ical shift change was slightly smaller in the 8-residue experiment
(Figures 2B and 2C). This indicates that the molecular recogni-
tion mechanism is essentially retained in the 8-residue peptide
in comparison with the 24-residue peptide. However, the 5-res-
idue peptide L(pS)D(pS)E showed only minor chemical shift
perturbation (Figures 2B and S1), indicating that this peptide
lost affinity despite including the LSDmotif and phosphorylation.
Thus, the LSD motif was not sufficient to bind to the SPOC
domain even though it was phosphorylated. We found that
additional N-terminal residues were required for interaction to
take place.reserved
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Figure 2. Binding of Phosphorylated SMRT to the SPOC Domain
(A) Chemical shift changes of the SPOC domain upon unphosphorylated 24-residue SMRT peptide binding (left) and doubly phosphorylated 24-residue SMRT
peptide binding (right). The 1H-15NHSQC spectra with 1:0, 1:0.5, 1:1, and 1:2molar ratios of 15N-labeled SPOCdomain and unlabeled SMRT peptide with/without
phosphorylation are shown by red, yellow, blue, and green, respectively.
(B) Chemical shift changes of the SPOC domain upon 24-, 8-, and 5-residue peptide bindings are shown as weighted average shift difference values, dave,
calculated as [d1H
2 + 0.14(d15N)
2]1/2, where d1H and d15N represent the difference in ppm between the free and complex forms.
(C) Difference of the chemical shift changes between 24- and 8-residue peptides as shown in Ddave, where the Ddave = dave(24)  dave(8).
(D) Mapping of the most-affected residues upon the ribbon model of the SPOC domain crystal structure (PDB ID code 1OW1). Residues with significant chemical
shift changes (dave(8) larger than 0.2) in the titration experiment using an 8-residue peptide (at 1:1 molar ratio) are colored in red.
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTStructure Determination of SPOC/Phosphorylated
SMRT Complex
To determine the SMRT interaction site on the SPOC domain, we
analyzed chemical shift changes of the HSQC spectrum from theStructure 22SPOC domain. We mapped residues whose chemical shift
changed dramatically upon the peptide p-SMRT-C8 (aa 2518–
2525, the C-terminal SMRT peptide double phosphorylated at
S2522 and S2524) binding onto the crystal structure of the, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 37
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Figure 3. Intermolecular NOEs
(A) Selected regions of the 3D 13C-edited NOESY spectrum of the complex formed between 13C,15N-labeled SMRT and the unlabeled SPOC domain. Intra-
molecular cross-peaks and diagonal peaks are shown in asterisk and cruciform, respectively.
(B) Selected regions of the 3D 13C-edited (F2)/
13C1,5N-filtered (F1) NOESYHSQC spectrum of the complex formed between
13C/15N-labeled SPOC and unlabeled
SMRT. Incompletely suppressed peaks are indicated by an X.
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTSMRT-free SPOC domain (Protein Data Bank [PDB] ID code
1OW1). Interestingly, the perturbed residues were confined to
a region around the strand b3 (around residue 3552) of the
SPOC domain (Figures 2B and 2D). Ariyoshi and Schwabe
(2003) previously described the interaction surface as deduced
from the inspection of crystal packing and mutagenesis. At the
N-terminal of the crystallized form, six residues stretched from
another molecule attached to the b3 strand (Figure S2A). Previ-
ous studies have proposed that the surface surrounding b3 rep-
resents the peptide binding region (Ariyoshi and Schwabe,
2003). The binding region we identified was almost identical to
that described in this previous report, although there was a
remarkable difference in the peptides used, specifically in the
sense that our peptide was phosphorylated, while that used in
the previous study was not.
We next determined the solution structure of the SPOC/
p-SMRT-C8 complex using heteronuclear NMR to reveal how
phosphorylation contributes to interaction. The use of chemically
synthesized and partially labeled SMRT peptide facilitated the
NMR assignment process (Mikami et al., 2013). Together with
the two-dimensional (2D) 13C, 15N-filtered (F2) TOCSY experi-
ment, we could assign 1H chemical shifts in an unlabeled part
of the SMRT peptide, such as Hb, Ha, and amide H of pS2522.38 Structure 22, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rightsNMR spectra used to monitor inter/intramolecular 1H-1H nu-
clearOverhauser effects (NOEs)were of adequatequality in order
to pursue structural determination of the complex. In particular,
Y2518 and L2521 of the labeled peptide providedwell-dispersed
and unambiguous intermolecular NOEs from the three-dimen-
sional (3D) 13C-edited NOESY HSQC experiment using an
unlabeled SPOC domain/13C, 15N DELY-labeled p-SMRT-C8
complex at an initial stage of manual identification of intermo-
lecular NOEs (Figure 3A). In addition to manually assigned NOE
cross-peaks, the inter- and intramolecular NOE cross-peaks
observed in the NOESY spectra were assigned by using an
automatic-iterative manner. Finally, intermolecular NOEs were
confirmed manually by a 3D 13C-edited (F2)/
13C1,5N-filtered (F1)
NOESY HSQC experiment using a 13C,15N-labeled SPOC
domain/unlabeled p-SMRT-C8 complex (Figure 3B). In total,
the solution structure of the SPOC/p-SMRT-C8 complex was
determined from over 4,000 NMR-derived distance restraints,
including 97 intermolecular distance restraints (Table 1).
The ensemble of 20 structureswas in excellent agreementwith
a large body of well-defined experimental data (Figure 4A; Table
1). The root-mean-square deviations (rmsds) of the backbone
and all heavy atoms of SPOC/p-SMRT-C8 complex were 0.38
and 0.82 A˚, respectively, except for disordered regions. Boundreserved
Table 1. NMR Structure Determination Statistics for the SPOC/
p-SMRT-C8 Complex
SA SAwater refined
Total number of distance
constraints
4,047
Intraresidue 754
Short range (ji  jj = 1) 973
Middle range (ji  jj = 2,3,4) 674
Long range (ji  jj > 4) 1,549
Intermolecular 97
Hydrogen bond constraints 94 3 2
Dihedral Constraints
f, 4, c1 129, 131, 40
Rmsds from experimental constraintsa
Distance (A˚) 0.0214 ± 0.0003 0.027 ± 0.001
Angle () 0.491 ± 0.06 0.79 ± 0.05
Rmsds from idealized covalent geometry
Bonds (A˚) 0.00141 ± 2 3 105 0.00423 ± 7
3 105
Angles () 0.318 ± 0.002 0.557 ± 0.009
Impropers () 0.206 ± 0.003 1.59 ± 0.07
PROCHECK Ramachandran plotb
Residues in most-favored
regions (%)
85.5 89.5
Residues in additionally
allowed regions (%)
12.9 9.0
Residues in generously
allowed regions (%)
0.2 0.6
Residues in disallowed
regions (%)
1.4 0.9
Average atomic rmsds from the average structure
Backbone (A˚) 0.30 0.38
All heavy (A˚) 0.74 0.82
These statistics comprise the lowest energy ensemble of the 20 struc-
tures obtained from 100 starting structures. Structure calculations were
performed using CNS (v. 1.2).
aNone of these structures exhibited distance violations >0.5 A˚ or dihedral
angle violations >5.
bEvaluated for the SPOC domain residues 3496–3540, 3546–3616, and
3624–3664 and the SMRT residues 2518–2522.
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTp-SMRT-C8 adopts an extended structure, the orientation of
the side chains of Y2518, E2519, L2521, and pS2522 are well
defined, supported by intermolecular NOEs. Of note, the 4.70
ppm intermolecular NOE observed from R3552Hgwas probably
due to hydrating water (Figure 3B), although the water(s) was not
implemented in the structure calculation. The last C-terminal
three residues, YETL(pS)D(pS)E, were not well defined in the
complex structure, implying that these residues are flexible,
even in complex (Figure 4A). In fact, {1H}-15N heteronuclear
NOE values of D2523 and E2525 were negative, indicating flexi-
bility of the C-terminal region in the complex state (Figure 4B).
Overall Structure of the Complex
The mainframe of the SPOC domain structure in complex with
p-SMRT-C8 was identical to that of the free SPOC structureStructure 22composed of a seven stranded antiparallel b sheet and six a
helices (Figure 4C). Interaction between the SPOC domain and
p-SMRT-C8 did not cause significant structural changes to the
SPOC domain. The atomic rms difference between the SPOC
domain in complex with the p-SMRT-C8 peptide and free
SPOC was 1.3 A˚ when backbone N, Ca, and C’ atoms of the
well-defined parts were superimposed.
As expected from our chemical shift perturbation experi-
ments, p-SMRT-C8 was bound to a hydrophobic shallow cleft
that was rich in basic residues at the rim (Figure 4D). p-SMRT-
C8 associates with SPOC in 1:1 stoichiometry and orientation
of the peptide relative to the SPOC domain is well defined,
consistent with the large number of NMR restraints (Figures 4A
and 4C; Table 1). The buried solvent-accessible area of the
SPOC/p-SMRT-C8 interface extends over 1,230 A˚2, including
various types of noncovalent interactions. The shallow hydro-
phobic cleft decorated by basic charges on the SPOC domain
is occupied by the side chain of L2521 from the LSD motif of
SMRT as a lid (Figure 4D).
Molecular Recognition of Phosphorylated SMRT by the
SPOC Domain
p-SMRT-C8 (YETL(pS)D(pS)E) is recognized by numerous inter-
molecular interactions by the SPOC domain. As described
above, our NMR titration showed that the N-terminal part
(Y2518, E2519, and T2520) is required for binding. In the
complex, the first residue (Y2518) forms hydrophobic interac-
tions with the hydrophobic side chains of M3553 and I3611
via its aromatic ring (Figure 4E). The E2519 side chain poten-
tially interacts with R3552 and R3554 via electrostatic inter-
actions or hydrogen bonding (Figure 4E). The side chain of
T2520 is exposed to the opposite side of the complex interface
and is therefore unlikely to play an important role in complex
formation. A possible hydrogen bond donor to the T2520
hydroxyl group is the side chain of Q3551 on strand b3
(Figure 4E).
Leu2521, the first residue of the LSDmotif, adjacent to the site
of CK2 phosphorylation, is docked into the small hydrophobic
cleft of the SPOC domain formed by strand b3 and the side
chain of I3549 and L3515 (Figure 4E). A striking feature of
SPOC/SMRT interaction is molecular recognition of the phos-
phate on pS2522 (CK2 site) by the SPOC domain. The phos-
phate group of pS2522 is located on the edge of a shallow cleft.
Although a lack of NMR distance information restricted interpre-
tation of the structure, and because phosphate does not provide
NOEs, the orientation of the side chain of pS2522 was defined
by intermolecular NOEs between side chain of K3516 and Hb
of pS2522. It appears that R3552, located close to the phos-
phate group of pS2522, is an attractive candidate as a residue
critical to hydrogen bond formation to the phosphate (Figure 4E).
In addition, positive charges of the side chain of two closely
located lysines (K3516 and K3606) potentially contribute to
binding via electrostatic interactions or hydrogen bonding with
the phosphate.
Notably, Y3602 also closely locates to the phosphate and
possibly contributes to the proper orientation of the side chains
of these two lysines (K3516 and K3606). The aliphatic side chains
of the lysines are located close to the side chain of Y3602 (Fig-
ure 4E). Those of the dCH2 signals of K3516 and K3606 showed, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 39
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Figure 4. Structure of the SPOC/p-SMRT-C8
Complex
(A) A best-fit superimposition of the final 20 simulated
annealing structures of the SPOC/p-SMRT-C8
with the lowest energies as determined by NMR. The
SPOC domain and SMRT peptide backbone are
colored cyan and green, respectively.
(B) {1H}-15N NOE values of synthesis DELY selective
13C,15N-labeled phosphorylated SMRT peptide in
complex with SPOC domain.
(C) The SPOC domain and SMRT peptide are de-
picted by ribbon model and stick representation,
respectively, using the same color and molecular
orientation as in (A).
(D) Electrostatic potential of the SMRT binding site of
the SPOCdomain. Molecular orientation of the image
is identical to (A). The surface is covered by electro-
static potential, where the potential is colored and
ranges from 2 kT/e in red to +2 kT/e in blue.
(E) Close-up view of the SMRT binding site of the
SPOC domain. The side chains of the SPOC domain
residues, which contribute to interaction with SMRT,
are shown and labeled. The residues of SMRT pep-
tide are labeled in italics. The site in which three
residues are disordered within the C-terminal of
SMRT is depicted by a dotted circle. Molecular
orientation is the same as in (A).
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTupfield shifts, 1.03 and 1.16 ppm respectively, probably due to
ring current shift caused by Y3602.
The last three C-terminal residues of p-SMRT-C8, D2523,
pS2524, and E2525 were mobile in the complex as shown in Fig-
ures 4A and 4B. Notably, however, the negatively charged side
chains of these residues potentially form electrostatic interac-
tions with R3548 located close by (Figure 4E).
Comparison between the crystal packing and SPOC/p-SMRT-
C8 complex structure revealed how crystal packing interac-
tion mimics phosphorylated SMRT peptide recognition. The
hydrophobic interactions mediated by Y2518 and L2521 of the
SMRT peptide are replaced by the hydrophobic interactions
mediated by V3496 and V3499, respectively, in the crystal pack-
ing (Figures S2A and S2B). In addition, the electrostatic interac-
tion mediated by E2519 of SMRT is replaced by the interaction40 Structure 22, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rights reservedmediated by D3497. Of note, instead of
the phosphate, the backbone carbonyl of
V3499 locates to a very similar position in
the crystal packing (Figures S2A and S2B).
SPR Analyses
NMR titration experiments using unphos-
phorylated and phosphorylated peptides
clearly showed that the SPOC domain pref-
erentially binds the phosphorylated peptide
as described. Furthermore, we performed
SPR analyses using the purified wild-type
SPOC domain and chemically synthesized
SMRT peptidewith various phosphorylation
patterns in order to quantify differences in
affinity. As expected, the KD value of double
phosphorylated peptide was significantlylower (approximately 100 times) than that of unphosphorylated
peptide. KD values for double phosphorylated and unphosphory-
lated peptides were 7.4 ± 2.4 3 107 M and 5.4 ± 5.6 3 105 M
(Figures 5A and 5B), respectively. Using isothermal titration calo-
rimetry (ITC), this increased affinity was confirmed in solution
state, and the obtained KD was almost consistent with SPR:
1.9 ± 1.8 3 107 M for doubly phosphorylated peptide (Fig-
ure 5C). Furthermore, the KD value of the CK2 single site
phosphorylated peptide obtained from SPR was 7.3 ± 2.9 3
107 M, comparable to that of the double phosphorylated
peptide (Figures 5A and 5B). In contrast, the single site phos-
phorylation of S2524 (putative CK1 site) showed a marginal
effect upon binding, and KD was determined as 3.1 ± 1.4 3
106 M (Figures 5A and 5B). These data indicate that
phosphorylation of the CK2 site is of critical importance for
AB
C Figure 5. In Vitro Binding Assay
(A) Equilibrium SPR analysis for the wild-type
SPOC domain with 24-residue SMRT peptides
(W/WO phosphorylation). The 24-residue peptides
were immobilized to the sensor chip.
(B) SPR analyses of mutants and the wild-type
SPOC domain with SMRT peptides. The yellow,
red, blue, and purple bars indicate affinities
shown as values of log(KD/M) for SMRT pep-
tides with double phosphorylation, phosphoryla-
tion of the S2522(CK2 site), phosphorylation of
the S2525(CK1 site), and nonphosphorylation,
respectively. To use a dimensionless number in
log, KD was divided by M. The asterisk repre-
sents log(KD/M) value <2.5, and the affinity was
too low to obtain accurate values by rigorous
analysis. The error bars represent SD from at least
three independent measurements.
(C) The top panel shows an ITC thermogram for
binding of thewild-type SPOCdomain to p-SMRT-
C8. The bottom panel shows the integrated heat of
each injection after correcting for the heat pro-
duced by diluting the SPOC domain.
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTSPOC/SMRT interaction, whereas phosphorylation of the CK1
site is of little importance.
We next carried out site-directed mutagenesis experiments in
order to assess the individual contribution of interfacial residues
of the SPOC domain toward the overall stability of the SPOC/
SMRT complex. To exclude the mutant, which was devoid of
appropriate folding, we accessed the tertiary structure of each
mutant by measuring NMR spectra (Figure S3). As a result, we
confirmed the structural integrity of all mutants, except for
I3549A and I3611A, which we were unable to express and purify.
As expected, Ala substitution of R3552, a key candidate resi-
due for pS2522 recognition, exhibited a dramatic reduction in
affinity (Figure 5B). To be noticed, affinities for all peptides
were significantly reduced. This implies that R3552 contributes
to interaction not only with the phosphate but also with other
acidic component, probably E2519, by electrostatic interactions
(Figure 4E). Interestingly, mutation of R3552 to Lys, which retains
basic charge, exhibited slight reduction of binding affinity but re-
tained tendency for differing affinities for various phosphoryla-
tion patterns on the SMRT peptide (Figure 5B). K3516A and
K3606A also exhibited greatly diminished binding for the CK2
phosphorylated SMRT peptide, consistent with the determined
structure. Furthermore, these residues also exhibit significantly
reduced affinities for other SMRT peptides similar to the case
of R3552A, implying that they also interact with an acidic partStructure 22, 35–46, January 7, 201other than the phosphate by long-range
electrostatic interaction (Figure 5B).
Notably, R3548A lost affinity in a
remarkable manner specifically to sin-
gle phosphorylated (CK1 site) SMRT
compared to the wild-type (Figure 5B).
In the determined structure, R3548 was
located in the vicinity of the phosphate
at the CK1 site, although the structure is
not converged and flexible (Figures 4A
and 4E). This significant reduction mayreflect the loss of electrostatic interaction between R3548 and
the CK1 site phosphate in vitro.
As a hydrophobic residue, L3515A showed reduction in affinity
(Figure 5B). I3549 and I3611 also contribute to intermolecular
interaction, judging from the determined structure. Nevertheless,
we were not able to produce I3549A and I3611Amutants as they
were formed within an inclusion body, and we could not there-
fore investigate their contribution to complex formation. How-
ever, this implies that such mutants lack the structural integrity
of the SPOC domain. Thus, I3549 and I3611 probably play an
important role in maintaining structure of the SPOC domain in
addition to stabilizing the complex. M3553A also showed a slight
reduction in affinity (Figure 5B).
As described, Y3602 contributes to the appropriate orienta-
tion of the side chains of the two lysines K3516 and K3606. As
expected, mutation of Y3602 to Ala, which lacks the aromatic
side chain, caused reduction in affinity (Figure 5B). Mutation of
Q3551, a potential hydrogen bond acceptor against T2520,
showed only marginal effect (Figure 5B).
Repression Analyses
The structural basis obtained from the SPOC/p-SMRT-C8 com-
plex structure in conjunctionwith SPR analysis was also tested in
living cells. Effects of SPOC domain mutations upon transcrip-
tion were analyzed by luciferase reporter assay using cultured4 ª2014 Elsevier Ltd All rights reserved 41
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Figure 6. Significance of Phosphorylation in Cell-Based Assays
(A) Relative activities of the luciferase reporter as determined by firefly luciferase units normalized to Renilla luciferase. All data represent mean values of three
independent experiments, and error bars represent SD. The error bars represent SD from at least three independent measurements.
(B) Intracellular localization of wild-type and mutants of HA-tagged GAL4-SPOC visualized by immunofluorescence. Scale bar represents 10 mm.
(C) Alteration in the electrophoretic mobility of SMRT. pFLAG-SMRT-C and pFLAG-SMRT-C (S2522A) were introduced into CV-1 cells. Whole-cell lysates were
resolved by SDS-PAGE and visualized by immunoblotting using an antibody specific for the FLAG tag. The lane labeled with TBCA represents the sample treated
with the CK2 inhibitor tetrabromocinnamic acid (TBCA) during cell culture, whereas the lane labeled with CIAP represents the sample treated with calf intestinal
alkaline phosphatase (CIAP) prior to SDS-PAGE and immunoblotting.
Structure
SPOC Domain Recognizes CK2 Phosphorylation of SMRTCV-1 cells. An expression vector for the SPOC domain fused to
the GAL4 DNA-binding domain (Gal4DBD-SPOC) and a GAL4-
responsive luciferase reporter vector were transfected, and lucif-
erase activities were measured. We confirmed that similar levels
of HA-taggedGAL4DBD-SPOCmutant proteins were expressed
in the transfected cells under the same condition of repression42 Structure 22, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rightsassay (Figure S4). As seen in SPR analyses, mutations of the
key residues for molecular recognition of phosphorylation at
the CK2 site, K3516A and R3552A, impaired the repression ac-
tivity of GAL4DBD-SPOC, and reporter activities were recovered
to a level similar to the Gal4DBD-only plasmid (Figure 6A). Mean-
while, mutation of L3515, which contributes to the complexreserved
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SPOC Domain Recognizes CK2 Phosphorylation of SMRTformation by hydrophobic interaction with L2515 of SMRT,
impaired repression in a moderate manner (Figure 6A). Mutation
of Y3602, which contributes to the appropriate side-chain con-
formations of K3516 and K3606, also moderately impaired
repression (Figure 6A). Interestingly, mutation of R3548 in the
vicinity of the phosphate group of the CK1 site in the determined
structure (Figure 4E) exhibited almost no effect upon repression
(Figure 6A). Thus, the significance of phosphorylation at the CK1
site was not evident in cultured cells. We also confirmed intracel-
lular localization patterns of themutants by immunofluorescence
(Figures 6B and S5). All mutants tested, including the mutants
K3516A andR3552, which impaired repression activity, localized
appropriately to the nucleus as with the wild-type, indicating that
mutations do not affect localization of the SPOC domain
(Figure 6B).
Phosphorylation on S2522
To characterize the phosphorylation of S2522 by CK2 in CV-1
cells, we monitored alteration in the electrophoretic mobility of
SMRTwith and without treatment with the specific CK2 inhibitor,
tetrabromocinnamic acid (TBCA). Prior to the phosphorylation
experiment using CV-1, we confirmed the direct phosphorylation
on S2522 by CK2 in vitro, using the purified GST-fused SMRT
peptide (YETLSDSE), GST-SMRT-C8. We detected the incorpo-
ration of 32P using 32P(g)-ATP for the GST-SMRT-C8 and that
this incorporation was abolished in the S2522A mutant GST-
SMRT-C8 (S2522A) (Figure S6). The inhibitor TBCA suppressed
such incorporation very effectively (Figure S6). These studies
indicate that the S2522 is the site of phosphorylation by CK2.
These results are consistent with the in vitro experiment previ-
ously reported (Zhou et al., 2001).
Next, the C-terminal part of SMRT (aa 2321–2525) fused to a
FLAG tag, and its S2522A mutant, FLAG-SMRT-C and FALG-
SMRT-C (S2522A), were expressed in CV-1 cells. Cells were
harvested and lysed, and whole-cell lysates were resolved
by SDS-PAGE and immunoblotting. FALG-SMRT-C showed
a delay in electrophoretic mobility against FALG-SMRT-C
(S2522A). Furthermore, treatment of FALG-SMRT-C with alka-
line phosphatase recovered mobility, indicating that FALG-
SMRT-C was phosphorylated at S2522 in CV-1 cells (Figure 6C).
Notably, FALG-SMRT-C expressed in the presence of TBCA
did not exhibit a delay in electrophoretic mobility (Figure 6C).
Thus, it could be concluded that the responsible kinase for
S2522 is CK2.
DISCUSSION
SPR analysis showed that single site phosphorylation on SMRT
by CK2 makes a significant contribution to binding affinity to the
SPOC domain. This is in stark contrast to the moderate effect of
phosphorylation upon the adjacent CK1 site (Figures 5A and 5B).
Paradoxically, Ala substitution of R3548 within the SPOC
domain, which is in the vicinity of the CK1 site phosphate in
the complex, showed loss of affinity for the single phosphory-
lated (CK1) SMRT peptide in SPR experiments, although re-
porter assays using CV-1 cells showed no effect for R3548A.
In contrast, remarkable effects for the Ala substitutions of
R3552 and K3516 within the SPOC domain, which were located
close to the CK2 site in the complex, were evident in both SPRStructure 22and reporter analyses. Collectively, these results suggest that
the SPOC domain, in terms of a molecule, is responsible mainly
for the molecular recognition of CK2 site phosphorylation and
can also recognize CK1 site phosphorylation. However, it is
possible that phosphorylation of the CK1 site of SMRT does
not occur in cells during the repression assay. In fact, a phos-
phor-proteomic approach recently surveyed widespread protein
phosphorylation and determined that the CK2 site of SMRT was
phosphorylated, whereas CK1was not (Olsen et al., 2006). As a
consequence, mutation of R3548, which is responsible for CK1
site recognition, showed no effect, whereas mutations of
R3552 andK3516, key residues for CK2 site recognition, showed
significant effects. In other words, the possibility of phosphoryla-
tion upon the CK1 site, or double phosphorylation events upon
SMRT in cells under specific conditions, has yet to be tested
and should be investigated in order to promote our understand-
ing of this important mechanism.
As key residues of SMRT for SPOC domain binding, NMR
binding analyses suggested that the N-terminal three residues,
Y2518, E2519, and T2520, are also required for binding in addi-
tion to the LSD motif and phosphorylation. Inspection of the
complex structure showed that Y2518 and E2519 are recog-
nized by SPOC domain residues, whereas T2520 is exposed to
the solvent (Figure 4E). Also, alanine substitution of Q3551, a
putative counterpart for T2520, showed subtle effects in SPR
analysis and reporter assays (Figures 5B and 6B). It is probable
that the T2520 residue existing between the N-terminal YE and
LSD motifs is not important for interaction but may play a role
as a spacer or linker. In fact, preliminary SPR analysis showed
that alanine mutations of Y2518 and E2519 resulted in loss of
affinity, whereas glycine mutation of T2520 retained affinity for
the SPOC domain (Figure S7). Collectively, these data might
suggest that YExL(pS)D could represent a possible core
sequence for SPOC domain binding.
We next contemplated the biological significance of CK2
phosphorylation. CK2 is known to localize to the nucleus,
cytoplasm, and plasma membrane and phosphorylates many
proteins as this promiscuous kinase targets a wide variety of
substrates (Litchfield, 2003; Pinna, 2002). In general, CK2 activ-
ity is closely related to cell state, such as viability, cell growth,
proliferation, the cell cycle, and cell survival (Cabrejos et al.,
2004; Duncan et al., 2010; Homma et al., 2002, 2005; Johnston
et al., 2002; Lin et al., 2006; Litchfield, 2003; Panova et al., 2006;
Pinna, 2002). It is thus interesting to speculate that CK2 phos-
phorylation of SMRT plays a role in crosslinking between the
transcriptional repression by SHARP and cell state. Phosphory-
lation on SMRT by CK2 may represent a ‘‘flag’’ providing infor-
mation concerning cell state and suggesting that the SPOC
domain may be a decoder. SHARP is known as an inducible
cofactor in hormone response and is able to repress SRA-medi-
ated transactivation by glucocorticoid receptor and estrogen
receptor in an autoregulatory manner (Shi et al., 2001). Presum-
ably, the phosphorylation by CK2 contributes to the fine-tuning
of hormonal response. Future OMICS studies for target genes
regulated by SHARP are now required in order to advance our
understanding of the regulatory mechanisms involved. Of partic-
ular note is the fact that DEK, a coactivator for the nuclear
receptor ecdysone receptor, is also phosphorylated by CK2 in
Drosophila, and such phosphorylation is prerequisite for DEK, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rights reserved 43
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SPOC Domain Recognizes CK2 Phosphorylation of SMRTactivity (Sawatsubashi et al., 2010). This also suggests that CK2
has an indispensable role in the precise regulation of hormone
response.
Throughout the cell cycle, SMRT and NCoR are known to
locate predominantly to the nucleus (Espinosa et al., 2002).
Consequently, phosphorylation is unlikely to exert effect upon
the intracellular localization of SMRT in clear contrast to the
well-studied STAT and SMADs (Darnell et al., 1994; Kretzschmar
andMassague´, 1998), which translocate from cytosol to nucleus
in response to specific phosphorylation. Rather, phosphoryla-
tion of SMRT by CK2 could be regarded as being a molecular
switch for the SPOC domain binding in the nucleus. In contrast,
it has been reported that MAPKs, MEK-1 and MEKK-1, phos-
phorylate SMRT, resulting in inhibition of repressive function
and perturbation in localization (Hong and Privalsky, 2000).
In addition, a recent SMRT/HDAC3 crystallographic study
showed that IP4 bound to the interface of SMRT/HDAC3, sug-
gesting an unknown regulation by IP4 (Watson et al., 2012b).
Interestingly, mice exhibiting point mutations at the interface in
both NCoR and SMRT lost HDAC3 activity in vivo (You et al.,
2013). It is noteworthy that we suggest an as-yet-unrecognized,
multilayered regulatory network that links transcription and other
cellular events by phosphorylation and that involves other post-
translational modifications and unknown ligands.
Apart from the SPOC domain, there are several domains
known to act as phosphorylated Ser binding modules, such as
MSH2, WD40, WW, BRCT, and CID domains, and 14-3-3 pro-
teins (Glover et al., 2004; Hao et al., 2007; Kubicek et al., 2012;
Meinhart and Cramer, 2004; Yaffe and Smerdon, 2001). Our
current experiment clearly showed that the SPOC domain
recognizes CK2 site phosphorylation on SMRT by a specific
interaction, such as K3516 and R3552 with the phosphate. We
thus suggest that the SPOC domain is a phosphorylated Ser
binding module, in addition to the already known ones.
We are also able to contemplate the diversity in structure and
function of the SPOC domain that has been distributed among
many proteins during evolution. Recently, the structure of the
ACID domain of Med25, a mediator component of the coactiva-
tor complex, which binds the transcriptional activation domain
(TAD) of VP16, has been characterized (Milbradt et al., 2011;
Vojnic et al., 2011). Literatures describe the site of interaction
for VP16 TAD within the ACID domain. Unexpectedly, the overall
structure of the ACID domain is reported to be similar to the
SPOC domain (Milbradt et al., 2011; Vojnic et al., 2011). Remark-
ably, the location of the VP16 binding site is similar to the SMRT
binding site within the SPOCdomain (Milbradt et al., 2011; Vojnic
et al., 2011). It is attractive to speculate that this architecture may
be widely used as a protein-protein interaction module in
different systems.EXPERIMENTAL PROCEDURES
Sample Preparation
The recombinant SPOC domain (aa 3496–3664) of human SHARP was ex-
pressed and purified as described previously (Mikami et al., 2013). Briefly, pro-
teins were expressed in Escherichia coli strain BL21 Rosetta (DE3) (Novagen)
as a fusion protein with glutathione S-transferase (GST). After the culture had
reached an OD660 value of 0.5, isopropyl-l-thio-b-D-galactopyranoside (IPTG)
was added to a final concentration of 1.0mM to induce protein expression. The
culture was incubated overnight at 20C. The harvested cells were suspended44 Structure 22, 35–46, January 7, 2014 ª2014 Elsevier Ltd All rightsin buffer containing 50 mM Tris-HCl (pH 8.0), 400 mM KCl, 1 mM dithiothreitol
(DTT), 0.1 mM EDTA, and 20% glycerol and were lysed by sonication under
ice-cold conditions. The cell lysate was centrifuged, and the supernatant
was loaded onto a DEAE Sepharose Fast Flow (GE Healthcare), followed by
a Glutathione Sepharose 4B (GE Healthcare) and was eluted by 30 mM
reduced glutathione. The N-terminal GST-tag was cleaved using HRV3C
proteinase. The target protein was purified by gel filtration (HiLoad 26/60
Superdex 75 pg, GE Healthcare) with buffer containing 30 mM HEPES
(pH 7.5), 150 mM KCl, 1 mM DTT, and 0.1 mM EDTA.
The mutant SPOC domain expression vectors were created by inverted
PCR. Following amplification of the vectors by inverted PCR using mutated
primers, the template was digested by DpnI. Introduction of the desired muta-
tion was confirmed by DNA sequencing. Mutant proteins were expressed and
purified in the same manner as the wild-type.
NMR Spectroscopy and Structure Calculation
NMR experiments were performed at 30C on a Bruker AVANCE 600 instru-
ment equipped with a TXI CRYOPROBE and a Bruker AVANCE 900 instrument
equipped with a TXI CRYOPROBE. For structure determination, the recombi-
nant SPOC domain (aa 3496–3664) of human SHARPwas used. The 8-residue
phosphorylated SMRT peptide p-SMRT-C8 (YETL(pS)D(pS)E), corresponding
to aa 2518–2525 of human SMRT, derived by solid-phase synthesis, was
purchased from TORAY Research Center. Commercially available 13C- and
15N-uniformly labeled F-MOC amino acid precursors (aspartic acid, glutamic
acid, leucine, and tyrosine [CIL]) were used for peptide synthesis and were
able to obtain DELY-selective 13C/15N-labeled phosphorylated peptide
(Mikami et al., 2013). The solution structure of the SPOC/p-SMRT-C8 complex
was determined using 0.9 mM complex solution in a buffer comprising 30 mM
HEPES (pH 7.5), 1 mM DTT, and 0.1 mM EDTA with 93% H2O/7%
2H2O or
99.9% 2H2O.
The sequential backbone resonance assignments in the complex were ob-
tained from four triple-resonance experiments: 3D HNCO, 3D HN(CA)CO, 3D
CBCA(CO)NH, and 3D HNCACB. The side-chain resonance assignments
were obtained from five spectra: 3D C(CO)NH, 3D HC(CO)NH, 3D HCCH-
TOCSY, 4D HC(CO)NH, and 1H-13C CT HSQC. The methyl resonances in
35/38 isopropyl groups of leucine and valine residues and 41/114 b-methylene
groups were assigned in a stereospecific manner as previously reported
(Mikami et al., 2013). The unlabeled part of the SMRT peptide was assigned
by a 2D 13C,15N-filtered (F2) TOCSY experiment using 13C,15N-labeled
SPOC domain/unlabeled p-SMRT-C8 complex sample.
The distance restraints derived by intramolecular NOEs were obtained
from 3D 15N-edited NOESY HSQC and 3D 13C-edited NOESY HSQC with
a mixing time of 100 ms. Intermolecular distance restraints were confirmed
by a 3D 13C-edited (F2)/
13C1,5N-filtered (F1) NOESY HSQC spectrum using
13C,15N-labeled SPOC domain/unlabeled phosphorylated SMRT peptide
sample. Dihedral f and c angles derived from TALOS+ were also utilized
(Shen et al., 2009). The 40 c1 rotamers of the side chains were estimated
from HNHB and HN(CO)HB experiments (Archer et al., 1991; Grzesiek
et al., 1992).
The program CYANA (v. 3.0) was used with the CANDID protocol for struc-
tural restraint collection (Herrmann et al., 2002). The CYANA library file of the
phosphorylated serine created by Craft and Legge (2005) was utilized. The
ensemble of 100 SPOC/p-SMRT structures was calculated using the CNS
program (v. 1.2) using a standard simulated annealing protocol (Bru¨nger
et al., 1998). Finally, structures were refined using a water refinement protocol
(Linge et al., 2003). To take account of intermolecular interaction, a loose 5 A˚
upper bound was also used (R3552Nh,Hh-S2522PO, K3516Nz-S2522PO
K3606Nz-S2522PO, and R3554Nz,Nε-E2519Oε).
The final 20 ensemble structures with the lowest energy were checked by
MOLMOL (Koradi et al., 1996), PROCHECK-NMR (Laskowski et al., 1996),
and MolProbity (Chen et al., 2010). Electrostatic potential on the protein sur-
face was calculated by APBS (v. 1.4) (Baker et al., 2001), and molecular
graphics were created by PyMOL (v. 1.5) (DeLano, 2002).
Chemical Shift Perturbation Experiments
Chemical shift perturbation experiments were performed using a 0.1 mM
15N-labeled SPOC domain in the NMR sample buffer described above. Unla-
beled SMRT peptide (24-residue w/wo phosphorylations and 5- and 8-residuereserved
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sample ratio of two equivalents. The 15N, HN chemical shift changes in the
SPOC domain were monitored in 1H-15N HSQC spectra. dave was calculated
as {[d1H
2 + 0.14(d15N)
2]}1/2, where d1H and d15N represent the difference in
ppm between the free and complex forms (Williamson, 2013).
In Vitro Binding Assay
Equilibrium surface plasmon resonance (SPR) measurements were carried
out using ProteOn XPR36 (BioRad). Biotinylated 24-residue human SMRT
polypeptides (aa 2502–2525) of various phosphorylation patterns were
purchased from TORAY Research Center. Peptides were coupled via the
N-terminal biotin moiety to a ProteOn NLC sensor chip (BioRad). Purified
proteins (300 nM–5 mM) were injected into both peptide-linked and nonlinked
sensor chip channels for correction of background signals. All binding
experiments were performed at 25C with a flow rate of 10 ml/min in a buffer
consisting of 10 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM DTT, and 0.05%
surfactant P20. Data were analyzed with ProteOn Manager Software. KD
values were obtained by taking an average of at least three independent
measurements.
The affinity for the wild-type SPOC domain/p-SMRT-C8(YETL(pS)D(pS)E)
interaction was also determined by isothermal titration calorimetry with a
ITC-200 (GE Healthcare) at 20C. Protein and p-SMRT-C8 were dialyzed
extensively into HEPES buffer (pH 7.5), 1mMDTT, and 0.1mMEDTA. The pro-
tein (0.5–1.0 mM) was titrated into 0.05–0.1 mM SMRT peptide. Data were
analyzed with Origin (v. 7.0) software. The affinity was estimated from the three
independent experiments.
Repression Assay
MH100-tk-luc and pCMX-Gal4-DBD were a kind gift from Professor Evans
R.M. (Salk Institute). The wild-type SPOC fragment was amplified by PCR
and cloned into pCMX-Gal4-DBD. The Gal4DBD-SPOC fragment was then
amplified from pCMX-Gal4-DBD-SPOC by PCR and cloned into the HA tag
vector. Gal4DBD-SPOC mutant-HA expression vectors were created by in-
verted PCR and DpnI digestion of the template. MH100-tk-luc, pRL-CMV,
and GAL4DBD-SPOC mutant expression vectors were transfected into CV-1
cells by Polyfect transfection reagent (QIAGEN) in accordance with the manu-
facturer’s protocol. After 24 hr transfection, cells were lysed and firefly and
Renilla luciferase activity were measured. Transfection efficiency was normal-
ized by Renilla luciferase activity.
Immunofluorescence
The HA-tagged GAL4DBD-SPOC mutant expression vector was transfected
into CV-1 cells (which were at approximately 60% confluency) using polyfect
transfection reagent. After 24 hr, cells were fixed with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100 in PBS, and immersed into 1% milk in
PBS. After blocking, cells were incubated with mouse monoclonal anti-HA
antibody (SIGMA) at room temperature (RT) for 1 hr, were washed with 0.1%
Tween20 in PBS, and were incubated with Alexa 488-conjugated anti-mouse
IgG (Invitrogen) at (RT) room temperature for 1 hr, followed by incubation with
DAPI at RT for 5 min. Cells were finally analyzed by fluorescent microscopy
(Leica).
Phosphorylation Assay
pFALG-SMRT-Cwas constructed by PCR using human SMRT (aa 2321–2525)
from the cDNA mixture QUICK-Clone cDNAs (Clontech) and was cloned into
pFLAG-CMV-2 (SIGMA). The S2522A mutation was introduced by inverted
PCR into pFALG-SMRT-C and designated as pFALG-SMRT-C (S2552A).
pFLAG-SMRT-C and pFLAG-SMRT-C (S2522A) were transfected into CV-1
cells using the Polyfect transfection reagent (QIAGEN). After 24 hr, cells
were suspended in MEM-0.1% FCS, and the CK2 inhibitor tetrabromocin-
namic acid (TBCA) (Calbiochem) in DMSO, was added (to a final concentration
of 50 mM). After further incubation for 8 hr, the cells were finally harvested and
lysed. Whole-cell lysates were analyzed by SDS-PAGE and immunoblotting
using a mouse monoclonal antibody specific for the FLAG tag (Sigma) and
HRP-anti-mouse Ig (DAKO). FLAG-SMRT-C was visualized by Clarity Western
ECL Substrate (BioRad). To check the phosphorylation, treatment with phos-
phatase for the lysate by 5U calf intestinal alkaline phosphatase (CIAP; Takara)
for 15 min at 30C was also performed.Structure 22ACCESSION NUMBERS
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